Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Comparative antiplatelet efficacy of a novel, nonpeptide GPIIb/IIIa antagonist (XV454) and abciximab (c7E3) in flow models of thrombosis
Autore:
Abulencia, JP; Tien, N; McCarty, OJT; Plymire, D; Mousa, SA; Konstantopoulos, K;
Indirizzi:
Johns Hopkins Univ, Dept Chem Engn, Baltimore, MD 21218 USA Johns Hopkins Univ Baltimore MD USA 21218 m Engn, Baltimore, MD 21218 USA DuPont Pharmaceut Co, Wilmington, DE USA DuPont Pharmaceut Co Wilmington DE USA Pharmaceut Co, Wilmington, DE USA
Titolo Testata:
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
fascicolo: 1, volume: 21, anno: 2001,
pagine: 149 - 156
SICI:
1079-5642(200101)21:1<149:CAEOAN>2.0.ZU;2-9
Fonte:
ISI
Lingua:
ENG
Soggetto:
GLYCOPROTEIN IIB/IIIA ANTAGONIST; VONWILLEBRAND-FACTOR BINDING; INDUCED PLATELET-AGGREGATION; SHEAR-STRESS; IN-VIVO; CORONARY ANGIOPLASTY; RECEPTOR BLOCKADE; ANTIBODY FRAGMENT; ACTIVATING-FACTOR; RANDOMIZED TRIAL;
Keywords:
platelets; adhesion; aggregation; shear stress; XV454, abciximab;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
39
Recensione:
Indirizzi per estratti:
Indirizzo: Konstantopoulos, K Johns Hopkins Univ, Dept Chem Engn, 3400 N Charles St, Baltimore, MD 21218USA Johns Hopkins Univ 3400 N Charles St Baltimore MD USA 21218
Citazione:
J.P. Abulencia et al., "Comparative antiplatelet efficacy of a novel, nonpeptide GPIIb/IIIa antagonist (XV454) and abciximab (c7E3) in flow models of thrombosis", ART THROM V, 21(1), 2001, pp. 149-156

Abstract

Glycoprotein (GP) IIb/IIIa is pivotal in homotypic platelet aggregation and may also be involved in the heterotypic adhesion of leukocytes and tumor cells to platelets. This study was primarily undertaken to compare the antiplatelet efficacy of a novel, nonpeptide GPIIb/IIIa antagonist, XV454, to that of abciximab in 2 now models of platelet thrombus formation: (1) directshear-induced platelet aggregation imposed by a cone-and-plate rheometer and (2) platelet adhesion onto von Willebrand factor (vWF)/collagen I followed by aggregation in a perfusion system. XV454 inhibited platelet aggregation in a concentration-dependent manner in both experimental models. Maximalinhibition of aggregation was achieved by XV454 at approximate to 70% receptor occupancy, which is lower than the greater than or equal to 85% previously reported for abciximab, At similar levels of receptor blockade (approximate to 45%), XV454 appeared to be relatively more effective than abciximab in suppressing platelet aggregation. Neither XV454 nor abciximab inhibited platelet adhesion to collagen. Pretreatment of surface-adherent plateletswith either XV454 or abciximab inhibited the attachment of monocytic THP-1cells under flow. In contrast, the rapidly reversible GPIIb/IIIa inhibitororbofiban failed to suppress these heterotypic interactions. These findings demonstrate that XV454 is a potent GPIIb/lIIa antagonist with a long receptor-bound lifetime like abciximab and may be beneficial for the treatment/prevention of thrombotic complications.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/11/20 alle ore 00:31:30